logo
Impact Radar
  • Overview
  • Impact Performance
  • Compare this company
  • All sources
    • Sign UpLog In
    logo

    Alnylam Pharmaceuticals Share | Sustainability & Chart

    US02043Q1076

    Basic information on the Alnylam Pharmaceuticals Share

    Location: United States

    Industry: Health Services

    Website

    knob-globe
    52%

    Impact Score

    Description Alnylam Pharmaceuticals Share

    Alnylam Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and commercializes RNA interference-based therapeutics to treat diseases with high unmet medical needs.

    Alnylam Pharmaceuticals Share Sustainability Performance

    Renewable Energy
    Greenhouse Gas Emissions
    Supply Chain
    Waste Recycling
    Sustainable
    Not yet sustainable
    Not sustainable
    No data
    We measure the sustainability of companies based on 12 criteria. Learn more about our method.

    Compare Alnylam Pharmaceuticals with ...

    Alnylam Pharmaceuticals

    ?

    Impact Score

    knob-globe
    52%
    knob-globe
    0%
    Climate
    Society
    Gender

    Sources of sustainability performance

    MetricValueUnitYearPDF NamePDF Page
    CEO-to-Employee Pay Ratio
    CEO nameYvonne Greenstreet2024alnylam-third-party-code-of-conduct.pdf2
    CEO-to-median-salary-ratio39ratio2024ALNY 2025 Proxy Statement (FINAL).pdf66
    Employee turnover rate
    Involuntary employee turnover5,9%2024alnylam-cr-report-2024.pdf94
    Voluntary employee turnover6,65%2024alnylam-cr-report-2024.pdf94
    Glass Ceiling
    Women in workforce56%2024alnylam-cr-report-2024.pdf44
    Women in management40%2024alnylam-cr-report-2024.pdf44
    Greenhouse Gas Emissions
    Number of employees2 230employees2024ALNY 2025 Proxy Statement (FINAL).pdf12
    Scope 1 emissions3 832Tons of CO2e2024alnylam-cr-report-2024.pdf67
    Scope 2 emissions, location based9 677Tons of CO2e2024alnylam-cr-report-2024.pdf67
    Harassment and Discrimination at the Workplace
    Anti-discrimination policyYes2024alnylam-third-party-code-of-conduct.pdf9
    Retaliation safeguardsYes2024alnylam-third-party-code-of-conduct.pdf14
    Confidentiality mechanismsYes2024alnylam-cr-report-2024.pdf79
    Incident notification mechanismYes2024alnylam-cr-report-2024.pdf79
    Supply Chain
    Scope 3 emissions160 413Tons of CO2e2024alnylam-cr-report-2024.pdf67
    Scope 2 emissions, location based9 677Tons of CO2e2024alnylam-cr-report-2024.pdf67
    Scope 1 emissions3 832Tons of CO2e2024alnylam-cr-report-2024.pdf67
    Number of employees2 230employees2024ALNY 2025 Proxy Statement (FINAL).pdf12
    Women on the Board
    Women on executive board3Members2024alnylam-cr-report-2024.pdf44
    Women on supervisory board5Directors2024alnylam-cr-report-2024.pdf44
    Supervisory board size12Directors2024alnylam-cr-report-2024.pdf44
    Executive board size10Members2024alnylam-cr-report-2024.pdf44
    Women in Management
    Women in management40%2024alnylam-cr-report-2024.pdf44
    Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

    Find more sustainable shares

    logo
    HomeFind Stocks & ETFsLearn to investAcademyGlossaryOur Method
    ImprintPrivacy PolicyGTCFAQContact UsAbout Us
    © 2025 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The source of ETF data is the websites and data sheets of the respective ETF providers.Logos provided by Clearbit (https://clearbit.com/). All trademarks and logos appearing on this website are the property of their respective owners and are used here for informational and educational purposes only, under fair use guidelines. We claim no affiliation with, nor endorsement by, the companies whose trademarks and logos are displayed. This website is independent of the brands analyzed and receives no direct or indirect compensation from them.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support!